{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:29:09Z","timestamp":1785536949810,"version":"3.56.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen. Twelve hundred fifty-eight postmenopausal women (aged 42\u201395 years) with osteoporosis (bone mineral density [BMD] of either lumbar spine or femoral neck at least 2.5 SDs below peak young adult mean or prior vertebral or hip fracture) were assigned to receive oral once-weekly alendronate, 70 mg (n = 519); twice-weekly alendronate, 35 mg (n = 369); or daily alendronate 10 mg (n = 370) for a total of 2 years of double-blind experience. Mean BMD increases from baseline (95% CI) at 24 months in the once-weekly, twice-weekly, and daily treatment groups, respectively, were 6.8% (6.4, 7.3), 7.0% (6.6, 7.5), and 7.4% (6.9, 7.8) at the lumbar spine and 4.1% (3.8, 4.5), 4.3% (3.9, 4.7), and 4.3% (3.9, 4.7) at the total hip. These increases in BMD as well as the BMD increases at the femoral neck, trochanter, and total body and the reductions of biochemical markers of bone resorption (urinary cross-linked N-telopeptides of type I collagen [NTx]) and bone formation (serum bone-specific alkaline phosphatase [BSAP]) were similar for the three dosing regimens. All treatment regimens were well tolerated with a similar incidence of upper gastrointestinal (GI) adverse experiences. The incidence rates of clinical fractures, captured as adverse experiences, were similar among the groups. The 2-year results confirm the conclusion reached after 1 year that once-weekly alendronate is therapeutically equivalent to daily dosing, providing patients with a more convenient dosing option that may potentially enhance adherence to therapy.<\/jats:p>","DOI":"10.1359\/jbmr.2002.17.11.1988","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:07Z","timestamp":1146096007000},"page":"1988-1996","source":"Crossref","is-referenced-by-count":170,"title":["Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1093","volume":"17","author":[{"name":"The Alendronate Once-Weekly Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Rizzoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f5pital Cantonal, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019055741300_bib1","first-page":"592","article-title":"Overview of patient compliance with medication dosing: A literature review","volume":"6","author":"Greenberg","year":"1984","journal-title":"Clin Ther"},{"key":"2024013019055741300_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00579707","article-title":"Non-compliance in elderly people: Evaluation of risk factors by longitudinal data analysis","volume":"18","author":"Lau","year":"1996","journal-title":"Pharm World Sci"},{"key":"2024013019055741300_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1345\/aph.18198","article-title":"Compliance with sulfonylureas in a health maintenance organization: A pharmacy record-based study","volume":"33","author":"Venturini","year":"1999","journal-title":"Ann Pharmacother"},{"key":"2024013019055741300_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024013019055741300_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024013019055741300_bib6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024013019055741300_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013019055741300_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2024013019055741300_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention Trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"key":"2024013019055741300_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(00)87974-6","article-title":"Weekly administration of alendronate: Rationale and plan for clinical assessment","volume":"22","author":"Bone","year":"2000","journal-title":"Clin Ther"},{"key":"2024013019055741300_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"2024013019055741300_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/jbmr.5650100610","article-title":"Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures","volume":"10","author":"Black","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013019055741300_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/BF01774010","article-title":"Quality control of DXA instruments in multicenter trials","volume":"5","author":"Faulkner","year":"1995","journal-title":"Osteoporos Int"},{"key":"2024013019055741300_bib14","first-page":"1905","article-title":"Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group","volume":"18","author":"ICH Harmonised Tripartite Guideline","year":"1999","journal-title":"Stat Med"},{"key":"2024013019055741300_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024013019055741300_bib16","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019055741300_bib17","first-page":"S56","article-title":"Consistency of effect of alendronate on reduction in risk of hip fractures","volume":"48","author":"Thompson","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"2024013019055741300_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1359\/jbmr.2000.15.2.183","article-title":"Bone matters: Are density increases necessary to reduce fracture risk?","volume":"15","author":"Faulkner","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019055741300_bib19","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019055741300_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(96)00102-0","article-title":"Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study","volume":"19","author":"Riis","year":"1996","journal-title":"Bone"},{"key":"2024013019055741300_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy","volume":"95","author":"Harris","year":"1993","journal-title":"Am J Med"},{"key":"2024013019055741300_bib22","first-page":"S209","article-title":"A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial","volume":"11","author":"Recker","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019055741300_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024013019055741300_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"key":"2024013019055741300_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"2024013019055741300_bib26","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019055741300_bib27","first-page":"S29","article-title":"Once-weekly alendronate 70 mg: Sustained suppression of bone resorption","volume":"13","author":"Bone","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019055741300_bib28","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2024013019055741300_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jbmr.5650060405","article-title":"The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats","volume":"6","author":"Seedor","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024013019055741300_bib30","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J Clin Invest"},{"key":"2024013019055741300_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"DeGroen","year":"1996","journal-title":"N Engl J Med"},{"key":"2024013019055741300_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019055741300_bib33","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1023\/A:1018894827961","article-title":"Esophageal irritation due to alendronate sodium tablets: Possible mechanisms","volume":"43","author":"Peter","year":"1998","journal-title":"Dig Dis Sci"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2002.17.11.1988","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/17\/11\/1988\/56467521\/5650171111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/17\/11\/1988\/56467521\/5650171111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:04:07Z","timestamp":1710327847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/17\/11\/1988-1996\/7592075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2002.17.11.1988","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,11,1]]},"published":{"date-parts":[[2002,11,1]]}}}